Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: A systematic review and meta-analysis

Abstract

Background:We conducted this meta-analysis to explore the tolerance of monotherapy with mirabegron (50mg) on an overactive bladder, compared with a common dosage of anticholinergic agents.Materials and methods:A comprehensive search for all randomized controlled trials that evaluated the safety of mirabegron and anticholinergic agents on overactive bladder was performed, and we searched the Cochrane Central Register of Controlled trials databases, Pubmed, Embase, and relevant trials from 2013.02 to 2019.10.Results:Eight studies included 5500 patients with treatment of monotherapy on overactive bladder were identified. The total number of treatment-emergent adverse events had no significantly difference between two monotherapies (RR=0.88 95%CI: 0.76-1.01; P=.08); however, patients would have a better tolerance with mirabegron (50mg) in adverse events of dry mouth (RR=0.42; 95%CI: 0.33-0.53; P